Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-26T16:35:36.281Z Has data issue: false hasContentIssue false

Impact of anti-inflammatory drugs on the risk of anxiety disorders after critical illness

Published online by Cambridge University Press:  23 March 2020

C.R. Medici*
Affiliation:
Aarhus University Hospital, Department of Clinical Epidemiology, Aarhus, Denmark Aarhus University Hospital, Psychiatric Research Academy, Department of Affective Disorders, Aarhus, Denmark
S.D. Østergaard
Affiliation:
Aarhus University Hospital, Department of Clinical Medicine, Aarhus, Denmark Aarhus University Hospital, Research Department P, Aarhus, Denmark
H.T. Sørensen
Affiliation:
Aarhus University Hospital, Department of Clinical Epidemiology, Aarhus, Denmark
C.F. Christiansen
Affiliation:
Aarhus University Hospital, Department of Clinical Epidemiology, Aarhus, Denmark
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Critical illness increases the risk of mental illness, including anxiety disorders. As critically ill patients exhibit high levels of inflammation and inflammation plays a role in mental illness, critical and mental illnesses may be linked by systemic inflammation.

Objective

To investigate whether anti-inflammatory drugs reduce the risk of subsequent anxiety disorders among intensive care patients requiring mechanical ventilation.

Aims

To assess the risk of anxiety disorders after intensive care requiring mechanical ventilation according to pre-admission use of non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, statins or combination. To compare risk in users with non-users.

Methods

This nationwide, registry-based, cohort study includes all patients receiving mechanical ventilation in Danish intensive care units during 2005–2013. Preadmission use of NSAIDs, glucocorticoids, statins or combinations will be identified from filled prescriptions. Risk of anxiety disorders in users and non-users of these anti-inflammatory drugs will be estimated using the cumulative incidence method, accounting for death as a competing risk. After propensity-score matching, risk in users and non-users will be compared using hazard ratios from a Cox regression.

Results

N/A. The estimated number of patients is 100,000. Expected preadmission use is 14% for statins, 15% for NSAIDs, and 10% for glucocorticoids. The study will have 95% power to detect a 10% decrease in risk between users and non-users.

Conclusions

N/A. The study potentially will contribute knowledge about the pathogenesis of anxiety disorders and a mechanism linking critical illness and mental illnesses. If anti-inflammatory drugs reduce risk of anxiety disorders, this may guide trials.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EW426
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.